Van ECK Associates Corp Has $3.54 Million Position in Organon & Co. (NYSE:OGN)

Van ECK Associates Corp cut its stake in Organon & Co. (NYSE:OGN - Free Report) by 19.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 245,591 shares of the company's stock after selling 57,588 shares during the period. Van ECK Associates Corp owned approximately 0.10% of Organon & Co. worth $3,541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. New York State Teachers Retirement System lifted its holdings in Organon & Co. by 20.1% in the fourth quarter. New York State Teachers Retirement System now owns 348,226 shares of the company's stock valued at $5,021,000 after acquiring an additional 58,321 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in Organon & Co. by 417.8% in the fourth quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company's stock valued at $2,267,000 after acquiring an additional 126,882 shares during the last quarter. KLCM Advisors Inc. lifted its holdings in Organon & Co. by 60.4% in the fourth quarter. KLCM Advisors Inc. now owns 999,099 shares of the company's stock valued at $14,407,000 after acquiring an additional 376,055 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in Organon & Co. by 59.1% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 221,461 shares of the company's stock valued at $3,193,000 after acquiring an additional 82,239 shares during the last quarter. Finally, UBS Group AG lifted its holdings in Organon & Co. by 88.3% in the third quarter. UBS Group AG now owns 657,912 shares of the company's stock valued at $11,421,000 after acquiring an additional 308,470 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OGN has been the topic of a number of research reports. The Goldman Sachs Group upped their price target on Organon & Co. from $18.00 to $20.00 and gave the stock a "neutral" rating in a research note on Friday. Piper Sandler upped their price target on Organon & Co. from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Monday, April 29th.

Insider Activity at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the acquisition, the insider now directly owns 15,181 shares of the company's stock, valued at approximately $278,723.16. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.17% of the stock is currently owned by corporate insiders.

Organon & Co. Stock Performance

Shares of Organon & Co. stock traded down $0.28 during trading hours on Tuesday, reaching $20.40. 2,438,043 shares of the company were exchanged, compared to its average volume of 2,727,833. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08. The stock's fifty day moving average is $18.25 and its 200 day moving average is $15.79. The firm has a market cap of $5.25 billion, a PE ratio of 5.08, a PEG ratio of 0.88 and a beta of 0.81.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Research analysts expect that Organon & Co. will post 4.1 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 5.49%. The ex-dividend date is Friday, May 10th. Organon & Co.'s dividend payout ratio (DPR) is presently 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.